Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Seragon

- PMLiVE

Roche gains rights to Innovent Biologics’ ADC candidate in deal worth over $1bn

IBI3009 targets an antigen significantly overexpressed in cancers including small cell lung cancer

- PMLiVE

Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma

Approximately 160,000 cases of the aggressive blood cancer are diagnosed globally every year

- PMLiVE

GSK and Rgenta to develop RNA-targeting small molecules in deal worth up to $500m per target

The alliance is aimed at advancing treatments for multiple disease areas, including oncology

- PMLiVE

Novartis’ Kisqali receives EC approval to treat early breast cancer patients

Approximately 70% of breast cancer cases are diagnosed in the early stages of the disease

- PMLiVE

Roche expands cell therapy capabilities with $1.5bn Poseida acquisition

The deal includes a BCMA-targeting allogeneic CAR-T therapy candidate for multiple myeloma

- PMLiVE

Merck gains rights to LaNova’s PD-1/VEGF bispecific antibody in deal worth over $3.2bn

A phase 1 clinical trial of the candidate in advanced solid tumours is currently enrolling patients

- PMLiVE

Roche and Flare Therapeutics enter oncology partnership worth over $1.8bn

The companies will aim to discover small molecule treatments aimed at previously undrugged transcription factor targets

Daiichi Sankyo logo

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu

The company will use Alteogen’s hybrozyme technology to advance the formulation

- PMLiVE

Merck acquires oncology spinout Modifi Biosciences in deal worth $1.3bn

The agreement gives Merck access to a new class of small molecules for difficult-to-treat cancers

- PMLiVE

Novartis’ Kisqali receives CHMP recommendation for early breast cancer patients

Approximately 70% of all breast cancer patients have HR-positive/HER2-negative disease

- PMLiVE

Pfizer and Triana enter molecular glue degrader partnership worth over $1.5bn

The companies will aim to discover new drugs for cancer and other severe diseases

- PMLiVE

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer

Just under 100 non-small cell lung cancer patients in England will be eligible for the drug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links